Points to consider for cost-effective use of biological and targeted synthetic DMARDs in inflammatory rheumatic diseases: results from an umbrella review and international Delphi study.
Céleste J T van der TogtBart Van den BemtDaniel AletahaRieke E AltenKaterina ChatzidionysiouJames B GallowayJohn IsaacDenis MullemanPatrick VerschuerenArnold G VultoPaco M J WelsingLise VerhoefAlfons A den BroederPublished in: RMD open (2023)
These points to consider can be used in rheumatology practices and complement inflammatory rheumatic disease treatment guidelines to incorporate cost-effectiveness in b/tsDMARD treatment.